Activation of dendritic cells and CD4 T-cells
Lymph node derived DCs in ILIT de novo- 3000 showed enhanced expression of T-cell co-stimulatory molecules. CD80 increased 4 weeks after treatment from mean MFI (median fluorescence intensity) 575.4 to 1050.0, p=0.04. CD86 increased from mean MFI 3934 to 6710, p=0.01, and CD141 from mean MFI 3975 to 6257, p=0.006. No changes in lymph node DC activation were detected in the placebo group. DCs in peripheral blood (PBL) did not change in any of the groups. (See Figure 5 and supplementary information.) The level of CD86 expression correlated to higher improvement scores on VAS in the active group, R2 =0.27, p=0.03. There was no correlation between the improvement and the expression of CD80 or CD141 and no correlations between any of the markers in the placebo group.
In PBL, there were no significant changes of the amount of CCR5+ CM T-cells or CD25++ CD4 EM T-cells. No significant difference in the amount of allergen activated CD4 T-cells could be detected between the placebo and active group after treatment. (See Figure E2 and supplementary information.)